RA101495-02.302
RA101495-02.302
A Phase 3, Multicenter, Open-Label Extension Study of Zilucoplan in Subjects with Generalized Myasthenia Gravis
Brief summary
The RAISE-XT study is an open-label extension study to evaluate the long-term efficacy, safety, and tolerability of zilucoplan in subjects with gMG who have previously participated in a qualifying Ra Pharmaceuticals sponsored zilucoplan study.
Medical Condition
Generalized Myasthenia Gravis
Min. Age
18
Years
Max. Age
-
Who Can Join?
All
Status
Active, not recruiting
Inclusion criteria
- Completion of a qualifying zilucoplan study
Exclusion criteria
- With the exception of a prior zilucoplan trial, participation in another concurrent clinical trial involving an experimental therapeutic intervention (participation in observational studies and/or registry studies is permitted)
Study Medication Description
Study Medication:
ZILBRYSQ®
Other Descriptive Name:
zilucoplan
Placebo
No
Comparator:
No
Refer to a friend
Study Dates
December 2019
Actual Start Date of Enrollment
June 2026
Planned Study Completion Date
General Information
Study ID:
RA101495-02.302
EudraCT Number:
2019-001565-33
CT.gov Number:
NCT04225871
Phase:
Phase 3